F-14/15, Orbit Mall, Civil Lines, Jaipur-302006
support@thetaxheaven.com
F-14/15, Orbit Mall, Civil Lines, Jaipur-302006 support@thetaxheaven.comSai Life Sciences Ltd is an Indian pharmaceutical company that focuses on drug discovery, contract research, and new chemical entities (NCEs). Many retail investors are showing interest in the company's IPO, especially after seeing its growth in the pharmaceutical and CDMO (Contract Development and Manufacturing Organization) sector. In this blog, we will understand Sai Life's business, IPO details, shareholding, and most importantly, its share price target from 2025 to 2030.
| Detail | Value |
|---|---|
| Current Share Price | ₹754.30 |
| Previous Close | ₹754.15 |
| Day's High | ₹758.50 |
| Day's Low | ₹736.50 |
| 52-Week High | ₹808.80 |
| 52-Week Low | ₹636.10 |
| Market Capitalization | ₹15,573 Cr |
| Beta (Volatility) | 1.30 |
| Face Value | ₹1 |
| Volume | 10,54,589 |
| VWAP | ₹745.65 |
Sai Life Sciences is a fast-growing pharmaceutical company offering services across the drug discovery and development value chain. It helps global pharma companies make new medicines through contract research, process development, and manufacturing.
Operates in CRO (Contract Research Organization) and CDMO sectors
Strong focus on R&D and new chemical entities
Clients include big global pharma companies from the US, Japan, and Europe
Facilities approved by international regulators
Sai Life Sciences is planning an IPO, according to the Red Herring Prospectus (RHP). Here are the important points:
IPO Size: Includes new issuance of equity shares
Use of Funds: General corporate purposes, repayment of outstanding borrowings, and expansion
Price Band: Yet to be announced officially, but expected in the range of ₹800 - ₹1,000
Lot Size: Will be revealed closer to IPO date
Anchor Investors: Likely to include big names like Morgan Stanley India Company Pvt Ltd, Kotak Mahindra Capital Company Ltd, Jefferies India Private Ltd, and IIFL Securities Ltd
Registrar: KFin Technologies Ltd
The IPO will give retail investors and qualified institutional buyers a chance to be part of a fast-growing pharma company.
| Shareholder Type | Holding (%) |
| Promoters | 35.17% |
| Retail & Others | 39.21% |
| Foreign Institutions | 12.36% |
| Mutual Funds | 11.54% |
| Other Domestic Institutions | 1.72% |
| Year | Minimum Target (₹) | Maximum Target (₹) |
| 2025 | 760 | 800 |
| 2026 | 850 | 900 |
| 2027 | 940 | 1,020 |
| 2028 | 1,050 | 1,120 |
| 2029 | 1,200 | 1,280 |
| 2030 | 1,300 | 1,450 |
These target prices are based on the company's strong performance in drug discovery, CDMO contracts, growing EBITDA, and favorable valuation.
IPO enthusiasm may push stock price up
Retail investors and anchor investors may support early growth
Advice: Early investors should monitor GMP (Grey Market Premium) before IPO listing.
Growth in international contract research services
Increased client base from Japan and Europe
Advice: Good time to start SIPs or long-term holdings if business performance is steady.
Positive revenue from drug discovery and manufacturing
Strong order book and recurring clients
Advice: Ideal year to increase portfolio exposure in pharma sector.
Premiumisation of product offerings
Rise in profitability and EBITDA margins
Advice: Consider holding for long term; attractive valuation for long-term investors.
Market expansion in US and Europe
High growth in custom chemical development
Advice: Reinvest dividends or SIP for compounding benefits.
Sai Life could become one of India's top CDMOs
Continued investment in infrastructure and R&D
Advice: Those who held from IPO can expect solid long-term gains.
Sai Life is a promising small cap company in India’s pharma space. With a strong focus on research, manufacturing, and global contracts, the company is expected to perform well. If you're a retail investor looking for long-term growth in the pharma sector, Sai Life Sciences IPO and stock could be a smart choice.
But remember, stock prices can go up and down. Always do your own research, read the Red Herring Prospectus (RHP), and consult a financial expert before investing.
This blog is only for informational purposes. It is not investment advice. Please consult SEBI-registered advisors before investing in the stock market.
Register & Login